ICUI

ANALYST NOTE: ICU MEDICAL, INC. (ICUI) DATE: 2026-06-13 SETUP STATUS: Actionable (Coil Confirmed)

1. Structural Readiness

As of the close on 2026-06-13, ICU Medical presents a confirmed coil setup. The structural readiness is active, indicating a breakout has fired.

• Conservative Entry: $162.17
• Current Price: $158.77
• Extension: -2.1% vs. conservative entry
• Breakout Level: The setup requires a close above the established breakout threshold (implied by the conservative entry of $162.17) to confirm the structural completion of the base.
• Volatility Context: The ATR at the time of the breakout was 3.4% (productive), and the current ATR is 3.3% (productive). This volatility profile sits within the historical "productive" range, suggesting sufficient structural quality for position sizing without the elevated risk associated with extreme volatility (>8%).

The presence of a confirmed coil is a positive readiness signal. The current price trading slightly below the conservative entry (-2.1%) represents a pullback within the active setup range, not a structural failure. The setup remains actionable pending a re-test of the breakout level or a sustained move higher.

2. The Thesis Layer

At this date, ICU Medical is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The conviction for this position must be derived strictly from the quality of the technical setup (the confirmed coil) and the immediate business fundamentals reported in the most recent filings, rather than a broad macroeconomic or industry-wide secular trend.

3. The Business

ICU Medical, Inc. is a medical technology firm specializing in the development, manufacture, and sale of devices for infusion therapy, vascular access, and critical care. The company operates globally, serving acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities (home health, long-term care).

Key Business Drivers & Evidence (as of 2026-06-13):

• Product Portfolio: The company offers a comprehensive range including needle-free connectors (MicroClave, NanoClave), infusion pumps (Plum 360, LifeCare PCA, Medfusion, CADD), and IV solutions. The Plum 360 software has been named "Best in KLAS" for eight consecutive years (2018–2025) and holds UL Cybersecurity Assurance Program Certification.
• Recent Regulatory Milestones:
• Plum Precision Pumps: The Plum Duo™ and Plum Solo™ received FDA 510(k) clearance in April 2025.
• Oncology Adjacency: In the period leading up to the current date, the company received approval for an adjacent oncology product bonding Clave connectors to access ports and non-PVC, non-DEHP IV bags.
• Pending Clearances: As of the May 2026 earnings call, the FDA is seeking additional testing data for the new Medfusion and CADD hardware submissions, requiring a larger sample size. Management's current strategy is to prioritize finishing testing on Medfusion before proceeding to CADD.
• Financial Structure & Margins:
• Divestiture Impact: On May 1, 2025, the company sold a 60% interest in its IV Solutions joint venture to OPF for $211.2 million, using $200 million to pay down Term Loan A. This divestiture of a lower-margin business drove consolidated gross margins up to 38.9% for the three months ended March 31, 2026, compared to 34.8% in the prior year.
• Revenue Growth: Infusion Systems revenue increased in Q2 2026, primarily driven by higher sales of LVP hardware. Management expects growth rates to return to historical levels for Q2 and the near term, absorbing the previously mentioned OEM wind-down.
• Customer Concentration: Net sales to a single distributor accounted for 20% of consolidated net sales in Q2 2026, up from 17% in the prior year.
• Cost Sensitivity: Management estimates that a $10 increase in the price of a barrel of oil results in $3 million of annualized incremental expense ($2M core, $1M JV), primarily driven by diesel costs passed through by freight carriers.
• Tariff Environment: Following a February 2026 Supreme Court ruling limiting the Administration's authority to impose tariffs under IEEPA, the company is evaluating potential refunds for tariffs already paid, which could be material.

4. Archetype and Conviction

Archetype: Growth Leader This classification is supported by the company's ability to deliver margin expansion through strategic divestiture (selling the lower-margin IV Solutions JV) while maintaining revenue growth in its core Infusion Systems segment. The "Growth Leader" label is reinforced by the successful launch of new FDA-cleared products (Plum Duo/Solo) and the continued dominance of the Plum 360 software ecosystem.

Conviction Factors:

• Thesis Strength: Moderate. The lack of a named secular thesis limits the "story" to tactical execution, but the business fundamentals are robust.
• Evidence Quality: High. The evidence base is dense with specific financial metrics (margin expansion to 38.9%), regulatory timelines (FDA testing for Medfusion/CADD), and strategic actions (JV sale).
• Structural Quality: The ATR of 3.3%–3.4% indicates a "productive" volatility environment, suitable for a mid-cap growth setup. The confirmed coil suggests institutional accumulation or a successful breakout attempt.
• Rerating Potential: The margin inflection from the JV sale provides a clear path to earnings quality improvement, which could support a multiple expansion if the pending FDA clearances for Medfusion and CADD are secured.

5. Invalidations, Strengtheners, and Gaps

What Would Strengthen the Case:

• FDA Clearance: Successful completion of the additional testing and receipt of 510(k) clearance for Medfusion and CADD hardware.
• Margin Sustainability: Confirmation that the 38.9% gross margin is sustainable in subsequent quarters, not just a one-time accounting effect of the divestiture.
• Tariff Recovery: A material cash recovery from the tariff refund evaluation.

What Would Invalidate the Case:

• Regulatory Delay: A significant, prolonged delay or denial of the FDA testing requirements for Medfusion/CADD, which management has identified as a key near-term risk.
• Margin Compression: A return to pre-divestiture margin levels or a failure to absorb the OEM wind-down as guided.
• Customer Concentration Risk: A further increase in reliance on the single distributor (currently 20%) or a loss of that contract.

Gaps in Evidence:

• Specific Guidance for Q3/Q4 2026: While management expects growth to return to historical levels, specific quantitative guidance for the remainder of 2026 is not detailed in the provided evidence beyond the general "historical levels" statement.
• OEM Wind-Down Specifics: The evidence mentions an "OEM wind down" but does not quantify the revenue impact or the timeline for its full absorption beyond the general expectation of absorbing it.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil setup with productive ATR (3.3%); Gross margin expansion to 38.9% driven by strategic JV divestiture; FDA clearance of Plum Duo/Solo pumps in April 2025. Key risks: FDA seeking additional testing data for Medfusion and CADD hardware; Single distributor concentration at 20% of sales; Oil price sensitivity impacting freight costs. Rating boundary: This is rated Buy rather than Strong Buy because the setup is currently trading -2.1% below the conservative entry, indicating a pullback that requires a re-test of the breakout level to confirm full structural completion. It is not rated Speculative because the business fundamentals (margin inflection, new product clearances) provide a solid floor of support. Sizing hint: Position size should reflect the current pullback within the confirmed coil; standard sizing for a mid-cap growth leader with productive volatility. Expected path: Management expects growth rates to return to historical levels in Q2 and near term; the company is prioritizing FDA testing completion for Medfusion and CADD; potential tariff refunds may provide a one-time cash benefit. Expected horizon: 3 to 6 months, contingent on the resolution of the FDA testing requirements for the new hardware submissions. Failure mode to watch: A significant delay or denial of FDA clearance for Medfusion and CADD, which would stall the growth narrative and potentially pressure the stock below the established structural base.